Biologic therapies for severe asthma
GG Brusselle, GH Koppelman - New England Journal of …, 2022 - Mass Medical Soc
Biologic Therapies for Severe Asthma Patients with severe asthma are at increased risk for a
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …
decreased quality of life, fixed airway obstruction, hospitalization, and death. Biologics may …
Biologics and airway remodeling in severe asthma
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in
part can become irreversible to conventional therapies, defining the concept of airway …
part can become irreversible to conventional therapies, defining the concept of airway …
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
JK Han, C Bachert, W Fokkens… - The Lancet …, 2021 - thelancet.com
Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …
general population, and long-term use of systemic corticosteroids is associated with adverse …
Management of severe asthma: a European respiratory society/American thoracic society guideline
This document provides clinical recommendations for the management of severe asthma.
Comprehensive evidence syntheses, including meta-analyses, were performed to …
Comprehensive evidence syntheses, including meta-analyses, were performed to …
[HTML][HTML] The cytokines of asthma
BN Lambrecht, H Hammad, JV Fahy - Immunity, 2019 - cell.com
Asthma is a chronic inflammatory airway disease associated with type 2 cytokines
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …
interleukin-4 (IL-4), IL-5, and IL-13, which promote airway eosinophilia, mucus …
[HTML][HTML] Type 2 inflammation in asthma and other airway diseases
J Maspero, Y Adir, M Al-Ahmad… - ERJ open …, 2022 - Eur Respiratory Soc
Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …
Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma
Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre …
A Menzies-Gow, M Gurnell, LG Heaney… - The Lancet …, 2022 - thelancet.com
Background No consensus exists on how to reduce oral corticosteroids after the initiation of
biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a …
biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a …
After asthma: redefining airways diseases
Executive summary Asthma is responsible for considerable global morbidity and health-care
costs. Substantial progress was made against key outcomes such as hospital admissions …
costs. Substantial progress was made against key outcomes such as hospital admissions …
[HTML][HTML] Tezepelumab in adults with uncontrolled asthma
J Corren, JR Parnes, L Wang, M Mo… - … England Journal of …, 2017 - Mass Medical Soc
Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …